| scholarly article | Q13442814 |
| P50 | author | Mostafa Fraig | Q47503102 |
| Eric Nuermberger | Q88595440 | ||
| Petros C Karakousis | Q90241891 | ||
| Gregory P Bisson | Q91276180 | ||
| Jacques Grosset | Q111670048 | ||
| P2093 | author name string | Zahoor Ahmad | |
| P2860 | cites work | A membrane protein preserves intrabacterial pH in intraphagosomal Mycobacterium tuberculosis | Q24650149 |
| Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus | Q28062241 | ||
| Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis | Q28145400 | ||
| The curious characteristics of pyrazinamide: a review | Q28191713 | ||
| A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection | Q28299361 | ||
| Pyrazinamide and pyrazinoic acid activity against tubercle bacilli in cultured human macrophages and in the BACTEC system | Q28329415 | ||
| Evidence that vesicles containing living, virulent Mycobacterium tuberculosis or Mycobacterium avium in cultured human macrophages are not acidic | Q28333302 | ||
| An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection | Q29616521 | ||
| Lack of acidification in Mycobacterium phagosomes produced by exclusion of the vesicular proton-ATPase | Q29617355 | ||
| Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates | Q29618010 | ||
| Comparison of the 'Denver regimen' against acute tuberculosis in the mouse and guinea pig. | Q33723589 | ||
| Evaluation of standard chemotherapy in the guinea pig model of tuberculosis | Q33826439 | ||
| Fast standardized therapeutic-efficacy assay for drug discovery against tuberculosis | Q33826465 | ||
| Intrapulmonary concentrations of pyrazinamide | Q33976873 | ||
| Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide | Q33991596 | ||
| Biphasic kill curve of isoniazid reveals the presence of drug-tolerant, not drug-resistant, Mycobacterium tuberculosis in the guinea pig. | Q34018978 | ||
| Activities of TMC207, rifampin, and pyrazinamide against Mycobacterium tuberculosis infection in guinea pigs | Q34483596 | ||
| Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide | Q34520476 | ||
| The antituberculous activity of pyrazinamide in vitro and in the guinea pig. | Q34537584 | ||
| Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid | Q34542604 | ||
| Pyrazinamide susceptibility and amidase activity of tubercle bacilli | Q34697358 | ||
| Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide | Q35139398 | ||
| Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice | Q35867048 | ||
| Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910. | Q36094916 | ||
| Metronidazole lacks antibacterial activity in guinea pigs infected with Mycobacterium tuberculosis | Q36949411 | ||
| Metronidazole lacks activity against Mycobacterium tuberculosis in an in vivo hypoxic granuloma model of latency | Q37109777 | ||
| Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs | Q37274688 | ||
| Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis | Q37392767 | ||
| Acid resistance in Mycobacterium tuberculosis | Q37494077 | ||
| The role of pyrazinamide in tuberculosis chemotherapy | Q39525867 | ||
| Present aspects of bacterial resistance in tuberculosis | Q40028686 | ||
| Local production of tumor necrosis factor and IFN-gamma in tuberculous pleuritis | Q40761026 | ||
| Clinical and toxicodynamic evidence that high-dose pyrazinamide is not more hepatotoxic than the low doses currently used | Q42111332 | ||
| The early bactericidal activity of drugs in patients with pulmonary tuberculosis | Q42257164 | ||
| Analysis of nitric oxide synthase and nitrotyrosine expression in human pulmonary tuberculosis | Q44064936 | ||
| Pyrazinamide is not active against Mycobacterium tuberculosis residing in cultured human monocyte-derived macrophages. | Q44501313 | ||
| Anaerobic incubation conditions enhance pyrazinamide activity against Mycobacterium tuberculosis | Q44991741 | ||
| Local production of nitric oxide in patients with tuberculosis. | Q45084084 | ||
| Pyrazinamide (aldinamide) in experimental tuberculosis of the guinea pig. | Q46526487 | ||
| Relapses after stopping chemotherapy for experimental tuberculosis in genetically resistant and susceptible strains of mice. | Q54353113 | ||
| The action of antituberculosis drugs in short-course chemotherapy. | Q54445022 | ||
| Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 month | Q67985481 | ||
| Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis: final report. East and Central African/British Medical Research Council Fifth Collaborative Study | Q68881337 | ||
| Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide | Q69802479 | ||
| Long-term follow-up of a clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council | Q69881424 | ||
| The treated pulmonary lesion and its tubercle bacillus. II. The death and resurrection | Q74062848 | ||
| Pyrazinamide (aldinamide) in the treatment of pulmonary tuberculosis | Q76088832 | ||
| Mechanisms of pyrazinamide resistance in mycobacteria: importance of lack of uptake in addition to lack of pyrazinamidase activity | Q78015492 | ||
| Studies on the gaseous content of tuberculous cavities | Q78723252 | ||
| Suitability of rifampicin for intermittent administration in the treatment of tuberculosis | Q93815424 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | tuberculosis | Q12204 |
| pyrazinamide | Q417571 | ||
| P304 | page(s) | 1527-1532 | |
| P577 | publication date | 2011-01-31 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis infections | |
| P478 | volume | 55 |
| Q36869913 | A Long-term Co-perfused Disseminated Tuberculosis-3D Liver Hollow Fiber Model for Both Drug Efficacy and Hepatotoxicity in Babies |
| Q27004482 | A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis |
| Q41996871 | A programme to create short-course chemotherapy for pulmonary Mycobacterium avium disease based on pharmacokinetics/pharmacodynamics and mathematical forecasting |
| Q46650295 | A rifapentine-containing inhaled triple antibiotic formulation for rapid treatment of tubercular infection |
| Q35411381 | Antitubercular effect of 8-[(4-Chloro phenyl) sulfonyl]-7-Hydroxy-4-Methyl-2H-chromen-2-One in guinea pigs |
| Q36921509 | Bedaquiline and Pyrazinamide Treatment Responses Are Affected by Pulmonary Lesion Heterogeneity in Mycobacterium tuberculosis Infected C3HeB/FeJ Mice |
| Q48713291 | Coadministration of Allopurinol To Increase Antimycobacterial Efficacy of Pyrazinamide as Evaluated in a Whole-Blood Bactericidal Activity Model |
| Q38039763 | Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis |
| Q37339276 | Concentration-Dependent Synergy and Antagonism of Linezolid and Moxifloxacin in the Treatment of Childhood Tuberculosis: The Dynamic Duo. |
| Q34058944 | Deficiency of double-strand DNA break repair does not impair Mycobacterium tuberculosis virulence in multiple animal models of infection. |
| Q37619123 | Drug regimens identified and optimized by output-driven platform markedly reduce tuberculosis treatment time |
| Q35037392 | Effectiveness of tuberculosis chemotherapy correlates with resistance to Mycobacterium tuberculosis infection in animal models |
| Q57095375 | Efficacy of pyrazinoic acid dry powder aerosols in resolving necrotic and non-necrotic granulomas in a guinea pig model of tuberculosis |
| Q36018624 | Evaluation of a mouse model of necrotic granuloma formation using C3HeB/FeJ mice for testing of drugs against Mycobacterium tuberculosis |
| Q34981779 | Host targeted activity of pyrazinamide in Mycobacterium tuberculosis infection |
| Q35743972 | Host-Mediated Bioactivation of Pyrazinamide: Implications for Efficacy, Resistance, and Therapeutic Alternatives |
| Q58799356 | Impact of immunopathology on the antituberculous activity of pyrazinamide |
| Q40634015 | Inhaled Pyrazinoic Acid Esters for the Treatment of Tuberculosis. |
| Q34729493 | Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients |
| Q34097641 | Local ischemia and increased expression of vascular endothelial growth factor following ocular dissemination of Mycobacterium tuberculosis |
| Q37138650 | Mycobacterial Protein Tyrosine Phosphatases A and B Inhibitors Augment the Bactericidal Activity of the Standard Anti-tuberculosis Regimen |
| Q36461593 | Old drugs, new purpose: retooling existing drugs for optimized treatment of resistant tuberculosis |
| Q38502298 | Pharmacokinetic-pharmacodynamic and dose-response relationships of antituberculosis drugs: recommendations and standards for industry and academia |
| Q45199376 | Population Pharmacokinetics of Pyrazinamide in Patients with Tuberculosis |
| Q37036499 | Potent rifamycin-sparing regimen cures guinea pig tuberculosis as rapidly as the standard regimen |
| Q28537952 | Preparation, characterization, and in vitro cytotoxicity evaluation of a novel anti-tuberculosis reconstruction implant |
| Q58729009 | Primary Lung Dendritic Cell Cultures to Assess Efficacy of Spectinamide-1599 Against Intracellular |
| Q38726482 | Pyrazinoic acid decreases the proton motive force, respiratory ATP synthesis activity, and cellular ATP levels |
| Q33798280 | Reduced emergence of isoniazid resistance with concurrent use of thioridazine against acute murine tuberculosis. |
| Q36086369 | Rifapentine is not more active than rifampin against chronic tuberculosis in guinea pigs |
| Q35164284 | Role of B cells and antibodies in acquired immunity against Mycobacterium tuberculosis |
| Q36571981 | Selective Inactivity of Pyrazinamide against Tuberculosis in C3HeB/FeJ Mice Is Best Explained by Neutral pH of Caseum |
| Q90051715 | The Bewildering Antitubercular Action of Pyrazinamide |
| Q21134950 | The role of the novel exopolyphosphatase MT0516 in Mycobacterium tuberculosis drug tolerance and persistence |
| Q38213320 | Therapeutic drug monitoring in the treatment of tuberculosis: an update |
| Q36844672 | Thioridazine lacks bactericidal activity in an animal model of extracellular tuberculosis. |
| Q42281128 | Treating tuberculosis with high doses of anti-TB drugs: mechanisms and outcomes. |
Search more.